Adjunctive lipid lowering therapy in the era of surrogate endpoints

Cardiology in Review

Volumn 19, Issue 1, 2011, Pages 17-22

  Silverman, Michael G ^a   Blaha, Michael J ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; coronary artery disease; ezetimibe; Niacin; surrogate markers

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TORCETRAPIB;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; ARTERIAL WALL THICKNESS; ARTHRALGIA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID INTIMA MEDIA THICKNESS; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE MARKER; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; LIPID ANALYSIS; LIVER TOXICITY; MALE; MONOTHERAPY; MYALGIA; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ATHEROSCLEROSIS; AZETIDINES; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYPOLIPIDEMIC AGENTS; NIACIN;

EID: 78650778472     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181fc212a     Document Type: Review

References (37)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14. randomised trials of statins. Lancet. 2005;366:1267-1278.
2. LaRosa J, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
3. Cannon C, Steinberg B, Murphy S, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-445. (Pubitemid 44109954)
4. Libby P. The forgotten majority: Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225-1228.
5. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113-2122.
6. Lee JM, Robson MD, Yu L-M, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787-1794.
7. Sibley CT, Gottlieb I, Cox C, et al. Comparative effect of statins vs. niacin on MRI measured regression of carotid atherosclerosis in a randomized clinical trial: The NIA plaque study. Abstract 685.
8. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: A systematic review. JAMA. 2007;298:786-798.
9. Kamanna V, Kashyap M. Mechanism of action of niacin. Am J Cardiol. 2008;101:20-26.
10. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
11. Birjmohun R, Hutten B, Kastelein J, et al. Efficacy and safety of high-density lipoprotein cholesterol increasing compounds. A meta-analysis of randomized control trials. J Am Coll Cardiol. 2005;45:185-197.
12. Brown B, Zhao X, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
13. Taylor AJ, Sullenberger LE, Lee HJ, et al. Atertial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
14. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243-2250.
15. Psaty B, Lumley T. Surrogate end points and FDA approval. A tale of 2 lipid-altering drugs. JAMA. 2008;299:1474-1476.
16. Knopp R, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-741.
17. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003;107:3124-3128.
18. Kastelein J, Akdim F, Stroes E, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
19. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes. The SANDS (stop atherosclerosis in native diabetics study) trial. J Am Coll Cardiol. 2008;52: 2198-2205.
20. Meaney A, Ceballos G, Asbun J, et al. The vytorin on carotid intima-media thickness and overall rigidity (VYCTOR) study. J Clin Pharmacol. 2009;49: 838-847.
21. Rossebo AB, Pederson TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
22. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER-6 HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis). J Am Coll Cardiol. 2010;55:2721-2726. doi:10.1016/j.jacc.2010.03.017.
23. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
24. Nissen SE, Tardif JC, Nicholls SJ, et al. Effects of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
25. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356: 1620-1630.
26. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and metaanalysis. Circulation. 2007;115:459-467.
27. Hodis H, Mack W, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128: 262-269.
28. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk. J Am Coll Cardiol. 2010;55:1600-1607.
29. Duivenvoorden R, de Groot E, Elsen BM, et al. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ Cardiovasc Imaging. 2009;2:235-242.
30. Desai MY, Bleumke DA. Atherosclerosis imaging using MR imaging: Current and emerging applications. Magn Reson Imaging Clin N Am. 2005;13:171-180.
31. Fayad ZA, Fuster V, Nikolaou K, et al. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: Current and potential future concepts. Circulation. 2002;106:2026-2034. (Pubitemid 35176312)
32. Stein EA. Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: More clarity or confusion? J Am Coll Cardiol. 2008;52:2206-2209.
33. Meuwese MC, Groot E, Duivenvoorden R, et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: The CAPTIVATE randomized trial. JAMA. 2009;301:1131-1139.
34. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826-832.
35. Atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes (AIM-HIGH) trial. Available at: Gttp://www.clinicaltrials.gov/ct/show/NCT00120289. Accessed January 19, 2010.
36. Heart Protection Study 2: Treatment of HDL to reduce the incidence of vascular events (HPS2-THRIVE) trial. Available at: Gttp://www.clinicaltrials. gov/ct/ showNCT00461630. Accessed January 19, 2010.
37. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574. doi: 10.1056/NEJMoa1001282.